Overview
LH market data
Price History
LH price chart
Valuation & Profitability
- P/E (TTM)
- 26.17 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $10.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.86 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.9% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 7.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $244.52 – $323.97 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $26.2B · P/B 2.41 · P/S 1.83.
Company News
8-K filing — LABCORP HOLDINGS INC. (LH)SEC EDGAR · Aug 14, 2026, 12:55 PM
Labcorp CEO Adam Schechter Sells 4,669 Shares for $1.5 MillionThe Motley Fool · Aug 12, 2026, 10:15 PM
Labcorp Announces FDA Approval Of PGDx elio Tissue Complete CDx As Companion Diagnostic To Identify Advanced Melanoma Patients With BRAF V600E/K VariantsBenzinga · Aug 10, 2026, 11:14 AM
Labcorp Announces Availability of Roche's Ventana Pten RxDx Assay, First Immunohistochemistry Companion Diagnostic Test Approved By FDA To Determine Pten Protein Loss In Prostate Adenocarcinoma PatientsBenzinga · Aug 4, 2026, 11:13 AM
JP Morgan Maintains Overweight on Labcorp Holdings, Raises Price Target to $360Benzinga · Aug 3, 2026, 3:36 PM
Morgan Stanley Maintains Overweight on Labcorp Holdings, Raises Price Target to $338Benzinga · Jul 31, 2026, 5:33 PM
Truist Securities Maintains Buy on Labcorp Holdings, Raises Price Target to $350Benzinga · Jul 31, 2026, 1:17 PM
Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $320Benzinga · Jul 31, 2026, 12:01 PM
Labcorp Holdings Raises FY2026 Adj EPS Guidance from $17.70-$18.35 to $18.10-$18.55 vs $18.01 Est; Raises FY2026 Sales Guidance from $14.650B-$14.800B to $14.710B-$14.827B vs $14.707B EstBenzinga · Jul 30, 2026, 10:51 AM
Laboratory Corp Q2 Adj. EPS $4.99 Beats $4.78 Estimate, Sales $3.731B Beat $3.711B EstimateBenzinga · Jul 30, 2026, 10:50 AM